TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06743009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N-lactoyl-phenylalanine
Description: Intravenous infusion of N-lactoyl-phenylalanine (Lac-Phe)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 0.9% isotonic NaCl infusion
Study: NCT06741683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection.
Study: NCT05598320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TransCon CNP
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
Study: NCT06253533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICVAX
Description: ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICVAX
Description: ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICVAX
Description: ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
Study: NCT05603741

Intervention type: DRUG
Group type: OTHER
Intervention: 0.9% Sodium Chloride Injection
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Injection 2%
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study: NCT06073951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Receive walking step goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in Mates in Motion program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Actigraph

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Garmin activity tracker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Garmin activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo walk-test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Undergo walk-test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05447312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Music Intervention
Description: Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Music Intervention
Description: Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
Study: NCT06531421

Intervention type: OTHER
Group type: OTHER
Intervention: Equity Report Cards
Description: At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
Study: NCT04814095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QOL
Description: QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT imaging
Description: CT radiographic imaging every 12 weeks +/- 2 weeks
Study: NCT06206226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHDC-DC
Description: 90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
Study: NCT05697211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg (Feraccru®)
Description: In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
Study: NCT06107634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastropexy
Description: In the intervention group, a three-point gastropexy is added to the repair. First, the right fundus flap is adapted posteriorly to the crural portion of the diaphragm with a 2-3 cm long running non-absorbable suture (posterior gastropexy). Second, the left fundus flap is adapted to the diaphragm anterolateral to the hiatus with a 2-3 cm long running non-absorbable suture (left anterolateral gastropexy). Finally, the minor curvature of the anterior stomach wall is adapted during reduced intraabdominal pressure to the anterior abdominal wall with a 2-3 cm long running non-absorbable suture (anterior gastropexy).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paraesophageal hernia repair
Description: Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraesophageal hernia repair
Description: Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
Study: NCT06465810

Intervention type: DRUG
Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Description: Data will be collected on patients with ATTR amyloidosis in a real-world setting

Intervention type: DRUG
Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Description: Data will be collected on patients with ATTR amyloidosis in a real-world setting

Intervention type: DRUG
Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Description: Data will be collected on patients with ATTR amyloidosis in a real-world setting
Study: NCT05078970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention+ (SPI+)
Description: SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Description: CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: This assigned condition tracks the care received in typical circumstances.
Study: NCT05041361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia (WBH)
Description: Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
Study: NCT04258917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study withdrawn
Description: Study withdrawn

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study withdrawn
Description: Study withdrawn
Study: NCT04924920

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SIGH
Description: To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEOT
Description: • The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: Bolus of fluids of 4 ml/kg given within 10 minutes
Study: NCT04740970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: JNJ-64304500 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection will be administered subcutaneously.
Study: NCT06334822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients are presented with one or more optional questionnaires (some validated, some bespoke)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients are presented with one or more optional questionnaires (some validated, some bespoke)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients are presented with one or more optional questionnaires (some validated, some bespoke)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device in pharmacy
Description: Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt device alerting system
Description: The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt device alerting system
Description: The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
Study: NCT04440254

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device
Description: Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
Study: NCT06307535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Caregivers
Description: MCP-C is a stakeholder-informed, innovative, manualized intervention designed to assist caregivers to connect to a sense of meaning and purpose in life, despite the challenges of caregiving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy for Caregivers
Description: Standard of care supportive psychotherapy
Study: NCT06101641

Intervention type: OTHER
Group type: OTHER
Intervention: Shellac nail polish application
Description: The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
Study: NCT04266275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin C3 Complex
Description: Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Study: NCT05737732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Effective Lighting
Description: Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
Study: NCT05688384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + Alfentanil
Description: In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
Study: NCT05600621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training (FLT) Workshops
Description: Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training (FLT) Workshops
Description: Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training (FLT) Workshops
Description: Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
Study: NCT05036785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of suture removal
Description: Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of suture removal
Description: Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery